Trial
NCT04220632
A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Collaborators
—
Condition
GVHD,Acute
Intervention
Itacitinib
Why stopped
Adverse events of the first patient
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-10-29